Paola Barbarino, MA, CEO of Alzheimer’s Disease International, raises concerns about the awareness, accessibility, and affordability of new disease-modifying therapies, namely anti-amyloid medications. High costs may prevent reimbursement for those who could benefit. Even before considering treatment costs, global diagnostic capabilities represent a huge barrier, with many healthcare systems lacking the resources and trained clinicians for accurate and timely diagnosis. Ms Barbarino highlights the scarcity of medical professionals who recognize dementia as a disease, citing the 2019 World Alzheimer’s Report where 62% of respondents did not view dementia as a disease, but a normal part of aging. The lack of understanding extends beyond the general public, affecting medical communities and contributing to the stigma surrounding dementia. This interview took place at the 18th Annual Congress on Controversies in Neurology (CONy 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
